Carbinoxamine maleate is effective for the symptomatic treatment of: Seasonal and perennial allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Dermatographism. As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have be...
Carbinoxamine maleate is contraindicated in children younger than 2 years of age (see CONTRAINDICATIONS ). Carbinoxamine maleate should be taken on an empty stomach with water. DOSAGE SHOULD BE INDIVIDUALIZED ACCORDING TO THE NEEDS AND THE RESPONSE OF THE PATIENT. Carbinoxamine maleate dosage should be based on the severity of the condition and the response of the patient. The drug is well tolerated in adults in d...
Carbinoxamine maleate is a histamine-H 1 receptor blocking agent.
Each tablet contains 4 mg carbinoxamine maleate and the following inactive ingredients: anhydrous lactose, magnesium stearate, microcrystalline cellulose, and sodium starch glycolate.
Each 5 mL (teaspoonful) of oral solution contains 4 mg carbinoxamine maleate and the following inactive ingredients: artificial bubble gum flavor, citric acid (anhydrous), glycerin, methylparaben, propylene glycol, propylparaben, purified water, sodium citrate (hydrous) and sorbitol solution.
Carbinoxamine maleate is freely soluble in water. Its structure is:
2-[(4-chlorophenyl)-2-pyridinylmethoxy]- N, N- dimethylethanamine (Z)-2-butenedioate (1:1)
C 16H 19CIN 2O·C 4H 4O 4
MW= 406.86
Carbinoxamine maleate, an ethanolamine derivative, is an antihistamine with anticholinergic (drying) and sedative properties. Carbinoxamine appears to compete with histamine (type H1) for receptor sites on effector cells in the gastrointestinal tract, blood vessels and respiratory tract.
Carbinoxamine is well absorbed from the GI tract and appears to be extensively metabolized by the liver, and excreted in the urine as inactive metabolites within 24 hours. Virtually no intact drug is extended in the urine.
In a study comparing a controlled-release suspension and a solution of carbinoxamine, healthy volunteers were administered a single dose of 8 mg carbinoxamine. A time to maximum concentration (Tmax) was between 1.5 hours to 5 hours, a peak plasma concentration (Cmax) of about 24 ng/mL was observed, and extent of exposure (AUC) was about 286 ng hr/mL. The serum half-life is reported to be 10 to 20 hours.
Carbinoxamine should not be used in patients with hypersensitivity to carbinoxamine. Carbinoxamine may increase the effects of other drugs such as barbiturates, TCAs, MAO inhibitors such as Phenelzine (Nardil), Tranylcypromine (Parnate), or Selegiline (Eldepryl), alcohol, other antihistamines, and CNS depressants. Carbinoxamine can be taken with or without food.
Cardiac effects, including prolongation of QT interval have not been adequately studied. Unlike other newer antihistamines, severe adverse cardiovascular effects are uncommon, and usually limited to over dosage situations.
Carbinoxamine should not be used in newborn or premature infants. Neonates have an increased susceptibility to anticholinergic side effects, such as CNS excitation, which may lead to convulsions.
Safe use of carbinoxamine during pregnancy has not been established. Therefore, carbinoxamine should not be used in women who are, or may become pregnant. Carbinoxamine is in the FDA pregnancy Category C.
Women who are breast-feeding should avoid use of carbinoxamine, since small amounts appear to be distributed into breast milk.
Carbinoxamine is more likely to cause dizziness, sedation, and hypotension in elderly patients. The incidence of adverse reactions is higher in the elderly; therefore, a dosing adjustment may be necessary in this subpopulation.
Carbinoxamine maleate is effective for the symptomatic treatment of:
Seasonal and perennial allergic rhinitis.
Vasomotor rhinitis.
Allergic conjunctivitis due to inhalant allergens and foods.
Mild, uncomplicated allergic skin manifestations of urticaria and angioedema.
Dermatographism.
As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled.
Amelioration of the severity of allergic reactions to blood or plasma.
Carbinoxamine maleate is contraindicated in children younger than 2 years of age.
Carbinoxamine maleate is contraindicated in nursing mothers.
Carbinoxamine maleate is contraindicated in patients who are hypersensitive to the drug or on monoamine oxidase inhibitor therapy. (See Drug Interactions section).
Deaths have been reported in children less than 2 years of age who were taking antihistamines, including carbinoxamine-containing drug products, therefore, carbinoxamine maleate is contraindicated in children younger than 2 years of age (see CONTRAINDICATIONS).
Antihistamines should be used with considerable caution in patients with: narrow angle glaucoma, stenosing peptic ulcer, symptomatic prostatic hypertrophy, bladder neck obstruction, pyloroduodenal obstruction.
As many other antihistamines, carbinoxamine maleate has an atropine-like action and, therefore, should be used with caution in patients with: increased intraocular pressure, hyperthyroidism, cardiovascular disease, hypertension.
Antihistamines such as carbinoxamine maleate should be not be used to treat lower respiratory tract symptoms, including asthma.
Carbinoxamine maleate may cause drowsiness; alcohol, sedatives, and tranquilizers may increase the drowsiness effect. Avoid alcoholic beverages while taking this product. Do not take this product if you are taking sedatives or tranquilizers, without first consulting your doctor. Use caution when driving a motor vehicle or operating machinery.
Monoamine oxidase inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines.
Carbinoxamine maleate has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc.).
No long-term studies in animals have been performed to determine the possible effects of carbinoxamine maleate on carcinogenesis, mutagenesis, and fertility.
Animal reproductive studies have not been conducted with carbinoxamine maleate. It is also not known whether carbinoxamine maleate can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Carbinoxamine maleate should be given to a pregnant woman only if clearly needed.
Because of the higher risk of antihistamines for infants generally and for newborns and prematures in particular, use of carbinoxamine maleate is contraindicated in nursing mothers (see CONTRAINDICATIONS section).
Carbinoxamine maleate is contraindicated in children younger than 2 years of age (see CONTRAINDICATIONS).
Neonates have an increased susceptibility to anticholinergic side effects, such as CNS excitation, which may lead to convulsions.
Carbinoxamine maleate may diminish mental alertness in children. In the young child, particularly, they may produce excitation.
Carbinoxamine maleate is more likely to cause dizziness, sedation, and hypotension in elderly patients (approximately 60 years or older). Sedating drugs may also cause confusion and over sedation in the elderly. Therefore, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic renal, or cardiac function, and of concomitant disease or other drug therapy.
The most frequent adverse reactions are underlined:
Body as a Whole: Urticaria, drug rash, anaphylactic shock, photosensitivity, excessive perspiration, chills, dryness of mouth, nose and throat.
Cardiovascular: Hypotension, headache, palpitations, tachycardia, extrasystoles.
Hematologic: Hemolytic anemia, thrombocytopenia, agranulocytosis.
Central Nervous System:Sedation, sleepiness, dizziness, disturbed coordination, fatigue, confusion, restlessness, excitation, nervousness, tremor, irritability, insomnia, euphoria, paresthesia, blurred vision, diplopia, vertigo, tinnitus, acute labyrinthitis, hysteria, neuritis, convulsions.
Gastrointestinal:Epigastric distress, anorexia, nausea, vomiting, diarrhea, constipation.
Urogenital: Urinary frequency, difficult urination, urinary retention, early menses.
Respiratory:Thickening of bronchial secretions, tightness of chest and wheezing, nasal stuffiness.
Antihistamine overdosage reactions may vary from central nervous system depression to stimulation. Stimulation is particularly likely in children. Atropine-like signs and symptoms- dry mouth; fixed, dilated pupils; flushing; and gastrointestinal symptoms may also occur.
Especially in infants and children, antihistamine overdosage may cause hallucinations, convulsions, or death.
The oral LD 50 of carbinoxamine maleate in guinea pigs is 411 mg/kg.
The treatment of overdosage with carbinoxamine maleate is essentially symptomatic and supportive. Vital signs (including respiration, pulse, blood pressure, and temperature) and EKG should be monitored. Induction of vomiting is not recommended. Activated charcoal should be given and gastric lavage should be considered after ingestion of a potentially life-threatening amount of drug. In the presence of severe anticholinergic effects, physostigmine may be useful. Vasopressors may be used to treat hypotension.
Carbinoxamine maleate is contraindicated in children younger than 2 years of age (see CONTRAINDICATIONS).
Carbinoxamine maleate should be taken on an empty stomach with water.
DOSAGE SHOULD BE INDIVIDUALIZED ACCORDING TO THE NEEDS AND THE RESPONSE OF THE PATIENT.
Carbinoxamine maleate dosage should be based on the severity of the condition and the response of the patient. The drug is well tolerated in adults in doses as high as 24 mg daily, in divided doses, over prolonged periods. On the other hand, some patients respond to as little as 4 mg daily.
Clinical experience suggests the following dosage schedules:
Tablets
Usual Adult Dosage: 1 or 2 tablets (4 to 8 mg) 3 to 4 times daily
Usual Child’s Dosage: Six to eleven years – ½ to 1 tablet (2 to 4 mg) 3 to 4 times daily
Oral Solution
Usual Adult Dosage: 1 or 2 teaspoonfuls (4 to 8 mg) 3 to 4 times daily
Usual Child’s Dosage (approximately 0.2 to 0.4 mg/kg/day, divided into 3 to 4 doses);
Six to eleven years – ½ to 1 teaspoonful (2 to 4 mg) 3 to 4 times daily.
Dosing for children 2 to 5 years of age should be based on weight whenever possible. The usual dosage for children 2 to 5 years of age is approximately 0.2 to 0.4 mg/kg/day, divided into 3 to 4 daily doses. In general, this corresponds to a dose of ¼ to ½ teaspoonful (1 to 2 mg) 3 to 4 times daily.
Carbinoxamine Maleate Tablets, USP 4 mg are supplied as white, round, scored tablets, debossed “PAL” on one side and score “4” on the other side, and are supplied in bottles of 100 tablets, NDC 46672-191-10 and bottles of 500 tablets, NDC 46672-191-50.
Carbinoxamine Maleate Oral Solution, 4 mg/5 mL is supplied as clear, colorless liquid with a bubble gum aroma, and is supplied in 4 oz bottles NDC 46672-644-04 and 16 oz bottles NDC 46672-644-16.
Store at 20°C to 25°C (68°F to 77°F) [See USP Controlled Room Temperature].
Dispense in a tight, light-resistant container with a child-resistant closure as defined in the official compendium.
Manufactured by:
MIKART, LLC
Atlanta, GA 30318
Code 838A00
Rev. 07/19
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| CARBINOXAMINE MALEATE | ACTIVE INGREDIENT | 02O55696WH | 1 | |
| CARBINOXAMINE | ACTIVE MOIETY | 982A7M02H5 | 1 | |
| ANHYDROUS CITRIC ACID | INACTIVE INGREDIENT | XF417D3PSL | 1 | |
| ANHYDROUS LACTOSE | INACTIVE INGREDIENT | 3SY5LH9PMK | 1 | |
| CELLULOSE, MICROCRYSTALLINE | INACTIVE INGREDIENT | OP1R32D61U | 1 | |
| GLYCERIN | INACTIVE INGREDIENT | PDC6A3C0OX | 1 | |
| MAGNESIUM STEARATE | INACTIVE INGREDIENT | 70097M6I30 | 1 | |
| METHYLPARABEN | INACTIVE INGREDIENT | A2I8C7HI9T | 1 | |
| PROPYLENE GLYCOL | INACTIVE INGREDIENT | 6DC9Q167V3 | 1 | |
| PROPYLPARABEN | INACTIVE INGREDIENT | Z8IX2SC1OH | 1 | |
| SODIUM CITRATE | INACTIVE INGREDIENT | 1Q73Q2JULR | 1 | |
| SODIUM STARCH GLYCOLATE TYPE A POTATO | INACTIVE INGREDIENT | 5856J3G2A2 | 1 | |
| SORBITOL | INACTIVE INGREDIENT | 506T60A25R | 1 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 46672-191 | 46672-191-10, 46672-191-50 |
| 46672-644 | 46672-644-04, 46672-644-16 |
Every source-derived ingredient row is available through these pages.
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION / TOPICAL | 216 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SHAMPOO / TOPICAL | 0.03 %w/w | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | POWDER, FOR SUSPENSION / ORAL | 8 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / AURICULAR (OTIC) | 63.64 %w/v | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | CLOTH / TOPICAL | 4.2 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | ENEMA / RECTAL | 0.02 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | OINTMENT / TOPICAL | NA | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | SOLUTION / OPHTHALMIC | 0.09 %w/v | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | DROPS / OPHTHALMIC | 0.01 %w/w | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION / SUBCUTANEOUS | 22 mg | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | SPRAY / NASAL | 5 mg | ||
| ANHYDROUS LACTOSE | ANHYDROUS LACTOSE | 3SY5LH9PMK | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 316 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | SUSPENSION, EXTENDED RELEASE / ORAL | 71 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | SOLUTION / OPHTHALMIC | 6 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION / IRRIGATION | 2 %w/v | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | TABLET, CHEWABLE / ORAL | 1.28 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | FILM, SOLUBLE / BUCCAL | 1 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION, SOLUTION / PARENTERAL | 30 mg | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | AEROSOL / TOPICAL | 0.08 %w/w | ||
| SORBITOL | SORBITOL | 506T60A25R | INJECTION / INTRALESIONAL | 45 %w/v | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | INJECTION, SOLUTION, CONCENTRATE / INTRAVENOUS | 81 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | AEROSOL, FOAM / TOPICAL | 1800 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / TOPICAL | 1971 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | LOTION / TOPICAL | 3392 mg | ||
| ANHYDROUS LACTOSE | ANHYDROUS LACTOSE | 3SY5LH9PMK | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 375 mg | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | INJECTION / INFILTRATION | 0.02 %w/v | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | SOLUTION / TOPICAL | 4.35 %w/v | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | ENEMA / RECTAL | 0.18 %w/v | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | POWDER / ORAL | 25 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOAP / TOPICAL | 0.76 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUPPOSITORY / VAGINAL | 227.9 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION / RECTAL | 0.13 %w/v | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION / ORAL | 346 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SUSPENSION / ORAL | 27120 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | GEL / OPHTHALMIC | 0.44 %w/w | ||
| SORBITOL | SORBITOL | 506T60A25R | TABLET / ORAL | 337.28 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SUSPENSION / SUBCUTANEOUS | 0.02 %w/v | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | TABLET / ORAL | 197 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | INJECTION, SOLUTION / INTRAMUSCULAR | 4000 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | EMULSION / TOPICAL | 0.2 %w/w | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SYRUP / ORAL | 40 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | TABLET, CHEWABLE / ORAL | 12 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SPRAY / SUBLINGUAL | 36 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SUSPENSION / OPHTHALMIC | 0.6 %w/v | ||
| SORBITOL | SORBITOL | 506T60A25R | SOLUTION/ DROPS / OPHTHALMIC | 0.25 %w/v | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | LIQUID / INTRAVENOUS | 18 mg | ||
| ANHYDROUS LACTOSE | ANHYDROUS LACTOSE | 3SY5LH9PMK | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 25 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | AEROSOL, FOAM / VAGINAL | 0.1 %w/w | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | POWDER, FOR SUSPENSION / ORAL | 120 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | TABLET, CHEWABLE / ORAL | 0.14 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | TABLET / ORAL | 1.8 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | OINTMENT / OPHTHALMIC | 0.01 %w/w | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | INJECTION / INTRAMUSCULAR | 6 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SPONGE / TOPICAL | 40 %w/w | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | INJECTION, SUSPENSION / INTRAMUSCULAR | 0.02 %w/v | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | FILM / SUBLINGUAL | 11 mg | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | SPRAY, METERED / NASAL | 1.2 mg/1ml | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | CAPSULE, DELAYED RELEASE / ORAL | 366 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | OINTMENT / RECTAL | 27 mg | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | SUSPENSION / RECTAL | 904 mg |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A040442-001 | CARBINOXAMINE MALEATE | CARBINOXAMINE MALEATE | 4MG | TABLET / ORAL | 2003-03-19 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A040442-001 | CARBINOXAMINE MALEATE | 4MG | TABLET / ORAL | 2003-03-19 | 84e616aacf4f… | ||
| 2026-08-18 06:07:40 | 2026-07 | A040442-001 | CARBINOXAMINE MALEATE | 4MG | TABLET / ORAL | 2003-03-19 | caaa826d4ba7… | ||
| 2026-02-19 14:30 UTC | 2026-02 | A040442-001 | CARBINOXAMINE MALEATE | 4MG | TABLET / ORAL | AA | RS | 2003-03-19 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A040442-001 | CARBINOXAMINE MALEATE | 4MG | TABLET / ORAL | AA | RS | 2003-03-19 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | A040442-001 | CARBINOXAMINE MALEATE | 4MG | TABLET / ORAL | AA | RS | 2003-03-19 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A040442-001 | CARBINOXAMINE MALEATE | 4MG | TABLET / ORAL | AA | RS | 2003-03-19 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A040442-001 | CARBINOXAMINE MALEATE | 4MG | TABLET / ORAL | AA | RS | 2003-03-19 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A040442-001 | CARBINOXAMINE MALEATE | 4MG | TABLET / ORAL | AA | RS | 2003-03-19 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A040442-001 | CARBINOXAMINE MALEATE | 4MG | TABLET / ORAL | AA | RS | 2003-03-19 | 2680178bc6a6… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A040442-001 | CARBINOXAMINE MALEATE | 4MG | TABLET / ORAL | AA | RS | 2003-03-19 | 5bbf6a4d5a75… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A040442-001 | CARBINOXAMINE MALEATE | 4MG | TABLET / ORAL | AA | RS | 2003-03-19 | d8e5a09893c0… |
| 2024-10-29 15:01 UTC | 2024-10 | A040442-001 | CARBINOXAMINE MALEATE | 4MG | TABLET / ORAL | AA | RS | 2003-03-19 | d06236e962d9… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A040442-001 | CARBINOXAMINE MALEATE | 4MG | TABLET / ORAL | AA | RS | 2003-03-19 | 79d66fd596c7… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A040442-001 | CARBINOXAMINE MALEATE | 4MG | TABLET / ORAL | AA | RS | 2003-03-19 | 301d65b070ca… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A040442-001 | CARBINOXAMINE MALEATE | 4MG | TABLET / ORAL | AA | RS | 2003-03-19 | 1e350fbaab3a… |
| 2024-05-31 18:47 UTC | 2024-05 | A040442-001 | CARBINOXAMINE MALEATE | 4MG | TABLET / ORAL | AA | RS | 2003-03-19 | 8072bd15b7f6… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A040442-001 | CARBINOXAMINE MALEATE | 4MG | TABLET / ORAL | AA | RS | 2003-03-19 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | A040442-001 | CARBINOXAMINE MALEATE | 4MG | TABLET / ORAL | AA | RS | 2003-03-19 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | A040442-001 | CARBINOXAMINE MALEATE | 4MG | TABLET / ORAL | AA | RS | 2003-03-19 | 4b0b4de00fa7… |
| 2019-12-13 00:20 UTC | 2019-12 | A040442-001 | CARBINOXAMINE MALEATE | 4MG | TABLET / ORAL | AA | RS | 2003-03-19 | 74a2ff9319b5… |
| 2022-03-09 01:35 UTC | 2022-03 | A040442-001 | CARBINOXAMINE MALEATE | 4MG | TABLET / ORAL | AA | RS | 2003-03-19 | bb7c543d1eb4… |
| 2021-12-28 21:50 UTC | 2021-12 | A040442-001 | CARBINOXAMINE MALEATE | 4MG | TABLET / ORAL | AA | RS | 2003-03-19 | 782e0a99824c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A040442-001 | CARBINOXAMINE MALEATE | 4MG | TABLET / ORAL | AA | RS | 2003-03-19 | 87673890dc5c… |
| 2021-03-12 10:30 UTC | 2021-03 | A040442-001 | CARBINOXAMINE MALEATE | 4MG | TABLET / ORAL | AA | RS | 2003-03-19 | 5aa47cf7b7d7… |
| 2020-12-22 03:56 UTC | 2020-12 | A040442-001 | CARBINOXAMINE MALEATE | 4MG | TABLET / ORAL | AA | RS | 2003-03-19 | 8869cabd3fbd… |
| 2020-11-12 02:37 UTC | 2020-11 | A040442-001 | CARBINOXAMINE MALEATE | 4MG | TABLET / ORAL | AA | RS | 2003-03-19 | c0c555d07b60… |
| 2019-12-14 00:12 UTC | 2019-12 | A040442-001 | CARBINOXAMINE MALEATE | 4MG | TABLET / ORAL | AA | RS | 2003-03-19 | 3f01610625f2… |
| 2019-09-15 20:21 UTC | 2019-09 | A040442-001 | CARBINOXAMINE MALEATE | 4MG | TABLET / ORAL | AA | RS | 2003-03-19 | b00525d2431f… |
| 2019-07-19 19:46 UTC | 2019-07 | A040442-001 | CARBINOXAMINE MALEATE | 4MG | TABLET / ORAL | AA | RS | 2003-03-19 | ea99ee380514… |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A040442-001 | CARBINOXAMINE MALEATE | 4MG | TABLET / ORAL | AA | RS | 2003-03-19 | 6a51e52b5d6a… |
| 2024-02-18 07:12 UTC | 2024-02 | A040442-001 | CARBINOXAMINE MALEATE | 4MG | TABLET / ORAL | AA | RS | 2003-03-19 | 1c564ffb4f44… |
| 2023-12-20 04:57 UTC | 2023-12 | A040442-001 | CARBINOXAMINE MALEATE | 4MG | TABLET / ORAL | AA | RS | 2003-03-19 | ea1830bbd6c7… |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A040442-001 | CARBINOXAMINE MALEATE | 4MG | TABLET / ORAL | AA | RS | 2003-03-19 | a72a2bbeb626… |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A040442-001 | CARBINOXAMINE MALEATE | 4MG | TABLET / ORAL | AA | RS | 2003-03-19 | 9b2671bbb829… |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A040442-001 | CARBINOXAMINE MALEATE | 4MG | TABLET / ORAL | AA | RS | 2003-03-19 | a67488948f0b… |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A040442-001 | CARBINOXAMINE MALEATE | 4MG | TABLET / ORAL | AA | RS | 2003-03-19 | 3f0d92c62455… |
| 2023-05-13 08:27 UTC | 2023-05 | A040442-001 | CARBINOXAMINE MALEATE | 4MG | TABLET / ORAL | AA | RS | 2003-03-19 | 053a50430f4f… |
| 2023-01-26 05:58 UTC | 2023-01 | A040442-001 | CARBINOXAMINE MALEATE | 4MG | TABLET / ORAL | AA | RS | 2003-03-19 | 3bdfa0b2c4d7… |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A040442-001 | CARBINOXAMINE MALEATE | 4MG | TABLET / ORAL | AA | RS | 2003-03-19 | 3a93d1ddd44b… |
| 2022-10-28 04:53 UTC | 2022-10 | A040442-001 | CARBINOXAMINE MALEATE | 4MG | TABLET / ORAL | AA | RS | 2003-03-19 | f41ea6bd6efb… |
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-02-19 14:30 UTC | 2026-02 | A040442-001 | AA | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A040442-001 | AA | 1 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | A040442-001 | AA | 1 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A040442-001 | AA | 1 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A040442-001 | AA | 1 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A040442-001 | AA | 1 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A040442-001 | AA | 1 | 2680178bc6a6… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A040442-001 | AA | 1 | 5bbf6a4d5a75… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A040442-001 | AA | 1 | d8e5a09893c0… |
| 2024-10-29 15:01 UTC | 2024-10 | A040442-001 | AA | 1 | d06236e962d9… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A040442-001 | AA | 1 | 79d66fd596c7… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A040442-001 | AA | 1 | 301d65b070ca… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A040442-001 | AA | 1 | 1e350fbaab3a… |
| 2024-05-31 18:47 UTC | 2024-05 | A040442-001 | AA | 1 | 8072bd15b7f6… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A040442-001 | AA | 1 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | A040442-001 | AA | 1 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | A040442-001 | AA | 1 | 4b0b4de00fa7… |
| 2019-12-13 00:20 UTC | 2019-12 | A040442-001 | AA | 1 | 74a2ff9319b5… |
| 2022-03-09 01:35 UTC | 2022-03 | A040442-001 | AA | 1 | bb7c543d1eb4… |
| 2021-12-28 21:50 UTC | 2021-12 | A040442-001 | AA | 1 | 782e0a99824c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A040442-001 | AA | 1 | 87673890dc5c… |
| 2021-03-12 10:30 UTC | 2021-03 | A040442-001 | AA | 1 | 5aa47cf7b7d7… |
| 2020-12-22 03:56 UTC | 2020-12 | A040442-001 | AA | 1 | 8869cabd3fbd… |
| 2020-11-12 02:37 UTC | 2020-11 | A040442-001 | AA | 1 | c0c555d07b60… |
| 2019-12-14 00:12 UTC | 2019-12 | A040442-001 | AA | 1 | 3f01610625f2… |
| 2019-09-15 20:21 UTC | 2019-09 | A040442-001 | AA | 1 | b00525d2431f… |
| 2019-07-19 19:46 UTC | 2019-07 | A040442-001 | AA | 1 | ea99ee380514… |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A040442-001 | AA | 1 | 6a51e52b5d6a… |
| 2024-02-18 07:12 UTC | 2024-02 | A040442-001 | AA | 1 | 1c564ffb4f44… |
| 2023-12-20 04:57 UTC | 2023-12 | A040442-001 | AA | 1 | ea1830bbd6c7… |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A040442-001 | AA | 1 | a72a2bbeb626… |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A040442-001 | AA | 1 | 9b2671bbb829… |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A040442-001 | AA | 1 | a67488948f0b… |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A040442-001 | AA | 1 | 3f0d92c62455… |
| 2023-05-13 08:27 UTC | 2023-05 | A040442-001 | AA | 1 | 053a50430f4f… |
| 2023-01-26 05:58 UTC | 2023-01 | A040442-001 | AA | 1 | 3bdfa0b2c4d7… |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A040442-001 | AA | 1 | 3a93d1ddd44b… |
| 2022-10-28 04:53 UTC | 2022-10 | A040442-001 | AA | 1 | f41ea6bd6efb… |
| 2022-09-29 23:25 UTC | 2022-09 | A040442-001 | AA | 1 | e64feba35796… |
| 2022-07-09 03:26 UTC · 3 captures of this ZIP | 2022-07 | A040442-001 | AA | 1 | cb3db0bc1861… |
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A040458-001 | CARBINOXAMINE MALEATE | CARBINOXAMINE MALEATE | 4MG/5ML | SOLUTION / ORAL | RS | 2003-04-25 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A040458-001 | CARBINOXAMINE MALEATE | 4MG/5ML | SOLUTION / ORAL | RS | 2003-04-25 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A040458-001 | CARBINOXAMINE MALEATE | 4MG/5ML | SOLUTION / ORAL | RS | 2003-04-25 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | A040458-001 | CARBINOXAMINE MALEATE | 4MG/5ML | SOLUTION / ORAL | RS | 2003-04-25 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A040458-001 | CARBINOXAMINE MALEATE | 4MG/5ML | SOLUTION / ORAL | RS | 2003-04-25 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | A040458-001 | CARBINOXAMINE MALEATE | 4MG/5ML | SOLUTION / ORAL | RS | 2003-04-25 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A040458-001 | CARBINOXAMINE MALEATE | 4MG/5ML | SOLUTION / ORAL | RS | 2003-04-25 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A040458-001 | CARBINOXAMINE MALEATE | 4MG/5ML | SOLUTION / ORAL | RS | 2003-04-25 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A040458-001 | CARBINOXAMINE MALEATE | 4MG/5ML | SOLUTION / ORAL | RS | 2003-04-25 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A040458-001 | CARBINOXAMINE MALEATE | 4MG/5ML | SOLUTION / ORAL | RS | 2003-04-25 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A040458-001 | CARBINOXAMINE MALEATE | 4MG/5ML | SOLUTION / ORAL | RS | 2003-04-25 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A040458-001 | CARBINOXAMINE MALEATE | 4MG/5ML | SOLUTION / ORAL | RS | 2003-04-25 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | A040458-001 | CARBINOXAMINE MALEATE | 4MG/5ML | SOLUTION / ORAL | RS | 2003-04-25 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A040458-001 | CARBINOXAMINE MALEATE | 4MG/5ML | SOLUTION / ORAL | RS | 2003-04-25 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A040458-001 | CARBINOXAMINE MALEATE | 4MG/5ML | SOLUTION / ORAL | RS | 2003-04-25 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A040458-001 | CARBINOXAMINE MALEATE | 4MG/5ML | SOLUTION / ORAL | RS | 2003-04-25 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | A040458-001 | CARBINOXAMINE MALEATE | 4MG/5ML | SOLUTION / ORAL | RS | 2003-04-25 | 8072bd15b7f6… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A040458-001 | CARBINOXAMINE MALEATE | 4MG/5ML | SOLUTION / ORAL | RS | 2003-04-25 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | A040458-001 | CARBINOXAMINE MALEATE | 4MG/5ML | SOLUTION / ORAL | RS | 2003-04-25 | 5d02ea3f76ae… | |
| 2022-04-04 05:41 UTC | 2022-04 | A040458-001 | CARBINOXAMINE MALEATE | 4MG/5ML | SOLUTION / ORAL | RS | 2003-04-25 | 4b0b4de00fa7… | |
| 2019-12-13 00:20 UTC | 2019-12 | A040458-001 | CARBINOXAMINE MALEATE | 4MG/5ML | SOLUTION / ORAL | RS | 2003-04-25 | 74a2ff9319b5… | |
| 2022-03-09 01:35 UTC | 2022-03 | A040458-001 | CARBINOXAMINE MALEATE | 4MG/5ML | SOLUTION / ORAL | RS | 2003-04-25 | bb7c543d1eb4… | |
| 2021-12-28 21:50 UTC | 2021-12 | A040458-001 | CARBINOXAMINE MALEATE | 4MG/5ML | SOLUTION / ORAL | RS | 2003-04-25 | 782e0a99824c… | |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A040458-001 | CARBINOXAMINE MALEATE | 4MG/5ML | SOLUTION / ORAL | RS | 2003-04-25 | 87673890dc5c… | |
| 2021-03-12 10:30 UTC | 2021-03 | A040458-001 | CARBINOXAMINE MALEATE | 4MG/5ML | SOLUTION / ORAL | RS | 2003-04-25 | 5aa47cf7b7d7… | |
| 2020-12-22 03:56 UTC | 2020-12 | A040458-001 | CARBINOXAMINE MALEATE | 4MG/5ML | SOLUTION / ORAL | RS | 2003-04-25 | 8869cabd3fbd… | |
| 2020-11-12 02:37 UTC | 2020-11 | A040458-001 | CARBINOXAMINE MALEATE | 4MG/5ML | SOLUTION / ORAL | RS | 2003-04-25 | c0c555d07b60… | |
| 2019-12-14 00:12 UTC | 2019-12 | A040458-001 | CARBINOXAMINE MALEATE | 4MG/5ML | SOLUTION / ORAL | RS | 2003-04-25 | 3f01610625f2… | |
| 2019-09-15 20:21 UTC | 2019-09 | A040458-001 | CARBINOXAMINE MALEATE | 4MG/5ML | SOLUTION / ORAL | RS | 2003-04-25 | b00525d2431f… | |
| 2019-07-19 19:46 UTC | 2019-07 | A040458-001 | CARBINOXAMINE MALEATE | 4MG/5ML | SOLUTION / ORAL | RS | 2003-04-25 | ea99ee380514… | |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A040458-001 | CARBINOXAMINE MALEATE | 4MG/5ML | SOLUTION / ORAL | RS | 2003-04-25 | 6a51e52b5d6a… | |
| 2024-02-18 07:12 UTC | 2024-02 | A040458-001 | CARBINOXAMINE MALEATE | 4MG/5ML | SOLUTION / ORAL | RS | 2003-04-25 | 1c564ffb4f44… | |
| 2023-12-20 04:57 UTC | 2023-12 | A040458-001 | CARBINOXAMINE MALEATE | 4MG/5ML | SOLUTION / ORAL | RS | 2003-04-25 | ea1830bbd6c7… | |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A040458-001 | CARBINOXAMINE MALEATE | 4MG/5ML | SOLUTION / ORAL | RS | 2003-04-25 | a72a2bbeb626… | |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A040458-001 | CARBINOXAMINE MALEATE | 4MG/5ML | SOLUTION / ORAL | RS | 2003-04-25 | 9b2671bbb829… | |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A040458-001 | CARBINOXAMINE MALEATE | 4MG/5ML | SOLUTION / ORAL | RS | 2003-04-25 | a67488948f0b… | |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A040458-001 | CARBINOXAMINE MALEATE | 4MG/5ML | SOLUTION / ORAL | RS | 2003-04-25 | 3f0d92c62455… | |
| 2023-05-13 08:27 UTC | 2023-05 | A040458-001 | CARBINOXAMINE MALEATE | 4MG/5ML | SOLUTION / ORAL | RS | 2003-04-25 | 053a50430f4f… | |
| 2023-01-26 05:58 UTC | 2023-01 | A040458-001 | CARBINOXAMINE MALEATE | 4MG/5ML | SOLUTION / ORAL | RS | 2003-04-25 | 3bdfa0b2c4d7… | |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A040458-001 | CARBINOXAMINE MALEATE | 4MG/5ML | SOLUTION / ORAL | RS | 2003-04-25 | 3a93d1ddd44b… | |
| 2022-10-28 04:53 UTC | 2022-10 | A040458-001 | CARBINOXAMINE MALEATE | 4MG/5ML | SOLUTION / ORAL | RS | 2003-04-25 | f41ea6bd6efb… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| a62ab885-5e2f-5b5b-e053-2995a90a8d44 | 748c233b-6ab9-42d0-89ab-e7ead30f7947 | 2020-05-21 | Warnings, Adverse reactions | a62ab885-5e2f-5b5b-e053-2995a90a8d44 748c233b-6ab9-42d0-89ab-e7ead30f7947 |
Adverse event summaries are temporarily unavailable. Other product information remains available.